Hopp til hovedinnhold

Kawasakis sykdom

Kawasakis sykdom er en febersykdom hos barn med utslett, slimhinneforandringer, øyekatarr, lymfeknuteforstørrelse på halsen og hudforandringer i fotsåler og håndflater. Tilstanden er selvbegrensende, men ubehandlet utvikles det hos 20-25 prosent utposninger på kransårene i hjertet.

Sist revidert:

QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/barn/ulike-sykdommer/kawasakis-syndrom/ 

Hva er Kawasakis sykdom?

Årsak

Symptomer

Diagnostikk

Behandling

Oppfølging

Prognose

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Kawasakis sykdom. Referanselisten for dette dokumentet vises nedenfor.

  1. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017; 135: e927. pmid:28356445 PubMed 
  2. Burns JC, Glodé MP. Kawasaki syndrome. Lancet 2004; 364: 533-44. PubMed 
  3. Saguil A, Fargo M, Grogan S.Diagnosis and management of Kawasaki disease. Am Fam Physician 2015 Mar 15;91(6):365-371.
  4. Freeman AF, Shulman ST. Kawasaki disease: Summary of the American Heart Association guidelines. Am Fam Physician 2006; 74: 1141-8. PubMed 
  5. Roed C, Skinhøj P. Kawasakis syndrom hos voksne. Ugeskr Læger 2009; 171: 430. Ugeskrift for Læger 
  6. Brogan P, Burns JC, Cornish J, et al. Lifetime cardiovascular management of patients with previous Kawasaki disease. Heart 2019. pmid:31843876 PubMed 
  7. Harnden A,Tulloh R, Burgner D. Kawasaki disease. BMJ. 2014 Sep 17;349:g5336. doi: 10.1136/bmj.g5336 DOI 
  8. Hoffmann TU, Pærregaard A. Kawasaki syndrom - en infektionssygdom?. Ugeskr Læger 2002; 164: 5934-6. PubMed 
  9. Leung DY, Meissner HC. The many faces of Kawasaki syndrome. Hosp Pract 2000; 35: 77 - 81, 85 - 6, 91 - 4.
  10. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020. doi:10.1016/ S0140-6736(20)31103-X
  11. Helle R, Alsaker T, Norgård G. Risikofaktorer ved Kawasakis syndrom. Tidsskr Nor Lægeforen 2004; 124: 1764-6. PubMed 
  12. Stapp J, Marshall GS. Fulfillment of diagnostic criteria in Kawasaki disease. South Med J 2000; 93: 44 - 77. PubMed 
  13. Stockheim JA, Innocentini N, Shulman ST. Kawasaki disease in older children and adolescents. J Pediatr 2000; 137: 250 - 2. PubMed 
  14. Yellen ES, Gauvreau K, Takahasi M, et. al. Performance of 2004 American Heart Association Recommendations for Treatment of Kawasaki Disease. Pediatrics 2010; 125: 234-41. Pediatrics 
  15. Nasjonalt kunnskapssenter for helsetjenesten. Rapport: Immunmodulerende behandling med IVIG gir effekt på noen nevrologiske sykdommer. Publisert 18.09.2008. www.kunnskapssenteret.no.
  16. Hamada H, Suzuki H, Onouchi Y, et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet 2019. pmid:30853151 PubMed 
  17. Platt B, Belarski E, Manaloor J, et al. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin. JAMA Netw Open 2020; 3: e1918565. pmid:31899532 PubMed 
  18. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012; doi:10.1016/S0140-6736(11)61930-2. DOI 
  19. Chen S, Dong Y, Yin Y, Krucoff MW. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart 2012. pmid:22869678 PubMed 
  20. Wardle AJ, Connolly GM, Seager MJ, et al. Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2017 Jan 27;1:CD011188. PMID: 28129459 PubMed 
  21. Tremoulet AH, Jain S, Jaggi P, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double blind, placebo-controlled trial. Lancet 2014. doi:10.1016/S0140-6736(13)62298-9 DOI 
  22. Zhao QM, Chu C, Wu L, et al. Systemic Artery Aneurysms and Kawasaki Disease. Pediatrics 2019. pmid:31732547 PubMed